Phaseline

Companies › Ace Cells Lab

Ace Cells Lab: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 4, 1 Phase 1; Ophthalmology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACE Reno
Standardized bioactive peptides and amino acids
–Phase 4Hypertensive NephropathyDec 2026
Stem Cells Fortified Eye Drops
Stem cell-derived biologic for ocular surface support
–Phase 4Dry Eye–
ACE Retino
Peptide-based therapy derived from fetal tissues, mesenchymal stem cells, and bioactive gr
–Phase 1Retinitis Pigmentosa (RP)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06787482ACE RetinoPhase 1Retinitis Pigmentosa (RP)OphthalmologyJun 2025
NCT07191847Stem Cells Fortified Eye DropsPhase 4Dry EyeOphthalmologyDec 2025
NCT07187713ACE RenoPhase 4Hypertensive NephropathyGenitourinaryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Ocugen Laboratoires Thea Beacon Therapeutics Huons Zhaoke (Guangzhou) Ophthalmology Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.